Trial Profile
Phase 2 study of abemaciclib (LY2835219) combination with BI 836845 in patients with HR+, HER2- metastatic breast cancer and other solid tumors
Status:
Planning
Phase of Trial:
Phase II
Latest Information Update: 18 Jul 2016
Price :
$35
*
At a glance
- Drugs Abemaciclib (Primary) ; Xentuzumab (Primary)
- Indications Advanced breast cancer; Solid tumours
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim
- 18 Jul 2016 New trial record